Feasibility and benefits of continuous glucose monitoring for type 1 diabetes in Rwanda: A real-world 12-month continuation phase.

Sandhya Narayanan^1,2, Jason Baker¹, John B Welsh², Giacomo Cappon³, Jean Claude Habineza^4,5, Simon P Niyonsenga⁶

¹Diabetes Empowerment International, New York, New York, USA.

²Dexcom, Inc., San Diego, California, USA.

³Department of Information Engineering, University of Padova, Padova, Italy.

⁴Rwanda Diabetes Association, Kigali, Rwanda.

⁵College of Medicine and Health Sciences, University of Rwanda, Kigali, Rwanda.

⁶Rwanda Biomedical Center, Kigali, Rwanda.

PubMed DOI

Abstract

AIMS: Continuous glucose monitoring (CGM) remains underutilized in low- and middle-income countries (LMICs). We extend earlier observations on the feasibility and impact of CGM among people living with type 1 diabetes (T1D) in Rwanda in a real-world continuation phase study. METHODS: This was a 1-year continuation phase of a single-arm, mixed-methods, prospective observational study conducted in…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.